Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica - United Kingdom
doi 10.3109/0284186x.2014.920960
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Bevacizumab and Chemotherapy for Recurrent Glioblastoma: A Single-Institution Experience

Neurology
Neurology
2009English

Sustained Focal Antitumor Activity of Bevacizumab in Recurrent Glioblastoma

Neurology
Neurology
2014English

Bevacizumab for Recurrent Hemangioendothelioma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

“Paradoxical” Findings of Tumor Vascularity and Oxygenation in Recurrent Glioblastomas Refractory to Bevacizumab

Oncotarget
Oncology
2017English

Bevacizumab and Fotemustine for Recurrent Glioblastoma: A Phase II Study of AINO (Italian Association of Neuro-Oncology)

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2013English

Single-Institution Retrospective Review of Patients With Recurrent Glioblastoma Treated With Bevacizumab in Clinical Practice

Health Science Reports
2019English

Bevacizumab Monotherapy for Temozolomide-Refractory Malignant Glioma

Japanese Journal of Neurosurgery
SurgeryNeurology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy